Skip to main content
Equibles
RARE logo

RARE · Ultragenyx Pharmaceutical Inc.

Track RARE — free

Use RARE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RARE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.08 -0.19 (-1.17%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$1.64B
Shares
101.92M
Volume · Nov 13 1.68M Avg daily vol (3M) 4.49M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.08 Open$16.30 Day$15.85–16.33 52W close$12.88–36.54 Avg vol 30d3.6M Short int23.6M · 23.2% of shares · 8.3d Short vol40% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Next earnings call
Feb 11, 2027 Est · unconfirmed · in 13 wks
Q3 2026 earnings call transcript
call held Nov 3, 2026
Play latest call

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA approvals for GENGLYCOS and FAYUVI amid revenue growth

Ultragenyx Pharmaceutical Inc. reported $523 million in nine-month revenue and $401 million in available cash as of September 30, 2026. GENGLYCOS and FAYUVI received FDA approvals, and the company expects $349 million in combined net PRV proceeds.

Revenue $173M ▲ 8.1% Net loss $118M Diluted EPS -$1.16
Read from the MD&A section
5 source passages
In August 2026, we announced the FDA granted accelerated approval for GENGLYCOS, in adult and pediatric patients eight years and older with GSDIa. In September 2026, we announced that the FDA granted standard full approval of FAYUVI for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). Our total revenues were $173 million and $523 million for the three and nine months ended September 30, 2026, respectively, and $160 million and $466 million for the three and nine months ended September 30, 2025, respectively. As of September 30, 2026, we had $401 million in available cash, cash equivalents, and marketable securities. We expect to receive combined net proceeds of $349 million from the sale of both PRVs. Open the document at this passage
Nov 3
Current report 8-K Events of Oct 30
20% workforce cut follows $210 million voucher sale

Ultragenyx Pharmaceutical Inc. received $210 million from its GENGLYCOS Priority Review Voucher sale on October 30, 2026 and plans a workforce reduction of approximately 20%, targeting 2027 R&D expenses of less than $350 million.

Completed an acquisition or sale of assets, Financial results, Exit or restructuring costs
4 source passages
On October 30, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) completed the previously disclosed sale (the “PRV Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. Pursuant to the terms of the PRV Asset Purchase Agreement, the Company received gross proceeds of $210 million from the buyer upon the closing of the PRV Sale. As part of the Restructuring, the Company is implementing a workforce reduction of approximately 20% of its employees (the “RIF”). the company has initiated substantial headcount and expense reductions and expects to reduce 2027 R&D expenses to less than $350 million Open the document at this passage
Oct 19
Current report 8-K
Other events

Ultragenyx and Baylor Research Institute settled patent litigation with Navinta over DOJOLVI, granting Navinta a non-exclusive, royalty-free license to market a generic version beginning January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted. Similar ANDA litigation remains pending.

Oct 14
Current report 8-K Events of Oct 8
Entered into a material agreement

Ultragenyx Pharmaceutical Inc. agreed on October 8, 2026 to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash upon closing, subject to customary closing conditions.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$730.00M
Trailing 12 months
Net income (TTM)
−$524.00M
Trailing 12 months
Revenue growth YoY
+8.1%
Year over year
Operating margin
-64.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-27.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$150.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.3%
Year over year · more shares
Price change (1Y)
-51.1%
Trailing year
Short interest
23.2%
Latest settlement · 8.3 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲29.5% $164.65M −$133.20M '24 Q4* ▲27.7% $139.00M −$151.00M '25 Q1 ▲13.6% $167.00M −$115.00M '25 Q2 ▲14.7% $160.00M −$180.00M '25 Q3 ▲25.7% $207.00M −$129.00M '25 Q4* ▼2.2% $136.00M −$185.00M '26 Q1 ▲28.1% $214.00M −$92.00M '26 Q2 LATEST ▲8.1% $173.00M −$118.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −29%
below
Price vs 50-day avg +5%
above
RSI (14) 49
neutral
MACD trend Positive
52-week position 14%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +11%
trailing
6-month return −31%
trailing
YTD return −30%
this year
Relative strength −31%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $23 — 200d above 50d
Institutional flow Accumulating
239 of 317 funds reported for Sep 30 · net +8.5M sh shares · +33 new
Insider flow Distributing
Net -$110.2K over 90 days · 100% sells
Short interest Rising
23.18% of shares out · ▲ +17.3% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
317 holders — near 3-yr high, broad support
Squeeze score 82
high risk · 0–100
Fundamentals
Fair
Revenue growth +20%
Y/Y
EPS growth +7%
Y/Y
Free cash flow $-472.0M
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −65%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Aug 4, 2026
Total revenue · full year 2026 Maintained $730M – $760M
May 5, 2026 $730M – $760M changed to Aug 4, 2026 $730M – $760M
prior FY $673M midpoint +10.7% Y/Y
Crysvita revenue · full year 2026 Maintained $500M – $520M
May 5, 2026 $500M – $520M changed to Aug 4, 2026 $500M – $520M
Dojolvi revenue · full year 2026 Maintained $100M – $110M
May 5, 2026 $100M – $110M changed to Aug 4, 2026 $100M – $110M
Previous outlook earlier release · from the Earnings Call filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Cresvita revenue · 2026 $500M – $520M
Pejolvi revenue · 2026 $100M – $110M
Guided vs delivered · last 4 settled
Total revenue full year 2025
guided $640M – $670M
$673M Beat +2.7%
Total revenue full year 2024
guided $500M – $530M
$560M Beat +8.7%
Total revenue full year 2023
guided $425M – $450M
$434M In line
Revenue in Ultragenyx territories 2021
guided $180M – $190M
$351.41M Beat +89.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−29% Bearish
Price vs 50-day avg
+5% Bullish
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
14% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $15 › 200d $23 — 200d above 50d
Institutional flow Accumulating
239 of 317 funds reported for Sep 30 · net +8.5M sh shares · +33 new
Insider flow Distributing
Net -$110.2K over 90 days · 100% sells
Short interest Rising
23.18% of shares out · ▲ +17.3% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
317 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13 Now $16 · 14% Range high $37
vs 200-day avg -29% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $436M June 30, 2026 —
Crysvita revenue $156M the three months ended June 30, 2026 —
Dojolvi revenue $27M the second quarter 2026 —
Evkeeza revenue $21M the second quarter 2026 —
Mepsevii revenue $10M the second quarter 2026 —
Net cash used in operations $97M the three months ended June 30, 2026 —
Non-cash stock-based compensation $34M Three Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RARE
Ultragenyx Pharmaceutical Inc.
this stock
$1.64B -30.1% +20.2% — 23.2%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
298
% held
116.6%
Reported
239 of 317
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
288
View
Short & Settlement
Short Interest Rising
Shares short
23.6M
Days to cover
8.3d
Change
+3.5M sh
View
Short Volume
Short vol %
40%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$25.0K
As of
Sep 23, 2026
View
Off-Exchange
Off-exchange %
42.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$110.2K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Sep 29, 2026
View
Financials
Financials
Revenue (FY)
$673.0M
Net income (FY)
$-575.0M
EPS diluted
$-5.83
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
35

Ultragenyx Pharmaceutical Inc. reported $523 million in nine-month revenue and $401 million in available cash as of September 30, 2026. GENGLYCOS and FAYUVI received FDA approvals, and the company expects $349 million in combined net PRV proceeds.

View
Proposed Sales
Value
$17.5K
Shares
1.3K
Filed
Sep 15, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Ultragenyx Reports Third Quarter…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
RARE +4.2% +10.6% -30.5% -0.1% -30.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +1.6% +11.8% -31.0% +0.1% -40.7%
Key facts CIK 1515673 CUSIP 90400D108 13F (30d) 200 filings 180 filers Visit website Investor relations